{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:53:30Z","timestamp":1792511610946,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The International Myeloma Working Group has recently revised the diagnostic criteria for primary plasma cell leukemia (PCL) to circulating plasma cells (CPCs) \u2265 5% in a peripheral blood smear. The present study validated new criteria in patients with multiple myeloma or PCL diagnosed using the previous diagnostic criteria, who were administered immunomodulatory drugs or proteasome inhibitors as induction therapy. We analyzed the medical records of 1357 patients from eight hospitals in South Korea. The median age of the all patients was 64 years, and 187 (13.8%) had CPCs at diagnosis. Only 79 (5.8%) of the patients had \u2265 5% CPCs. The median overall survival (OS) of patients with CPCs \u2265 5% and \u2265 20% was similar, but had significantly inferior median progression-free survival (PFS) and median OS than those with CPCs &lt; 5% (13.1 vs. 21.5 months, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001, and 21.5 vs. 60.9 months, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001, respectively). Primary PCL diagnosed using the revised criteria presented with higher total calcium levels and serum creatinine levels, lower platelet counts and frequent organomegaly and plasmacytoma at diagnosis. Univariate and multivariate analyses demonstrated that the presence of plasmacytoma and elevated serum \u03b22-microglobulin were significantly associated with OS in primary PCL. In conclusion, the revised criterion of CPCs \u2265 5% in a peripheral blood smear is appropriate for PCL diagnosis.<\/jats:p>","DOI":"10.1038\/s41408-022-00755-w","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T04:12:11Z","timestamp":1669003931000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Validation of the revised diagnostic criteria for primary plasma cell leukemia by the Korean Multiple Myeloma Working Party"],"prefix":"10.1038","volume":"12","author":[{"given":"Sung-Hoon","family":"Jung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5878-8895","authenticated-orcid":false,"given":"Kihyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Eun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3756-796X","authenticated-orcid":false,"given":"Joon Ho","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2375-8140","authenticated-orcid":false,"given":"Dajung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Kyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung Ha","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kawi Han","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4635-5697","authenticated-orcid":false,"given":"Je-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,21]]},"reference":[{"key":"755_CR1","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1080\/17474086.2019.1598258","volume":"12","author":"P Musto","year":"2019","unstructured":"Musto P, Statuto T, Valvano L, Grieco V, Nozza F, Vona G, et al. An update on biology, diagnosis and treatment of primary plasma cell leukemia. Expert Rev Hematol. 2019;12:245\u201353.","journal-title":"Expert Rev Hematol"},{"key":"755_CR2","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1093\/annonc\/mdq646","volume":"22","author":"L Pagano","year":"2011","unstructured":"Pagano L, Valentini CG, De Stefano V, Venditti A, Visani G, Petrucci MT, et al. Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. Ann Oncol. 2011;22:1628\u201335.","journal-title":"Ann Oncol"},{"key":"755_CR3","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1001\/archinte.133.5.813","volume":"133","author":"RA Kyle","year":"1974","unstructured":"Kyle RA, Maldonado JE, Bayrd ED. Plasma cell leukemia. Report on 17 cases. Arch Intern Med. 1974;133:813\u20138.","journal-title":"Arch Intern Med"},{"key":"755_CR4","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/leu.2012.336","volume":"27","author":"C Fern\u00e1ndez de Larrea","year":"2013","unstructured":"Fern\u00e1ndez de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia 2013;27:780\u201391.","journal-title":"Leukemia"},{"key":"755_CR5","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.3324\/haematol.2016.158303","volume":"102","author":"M Granell","year":"2017","unstructured":"Granell M, Calvo X, Garcia-Gui\u00f1\u00f3n A, Escoda L, Abella E, Mart\u00ednez CM, et al. Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. Haematologica 2017;102:1099\u2013104.","journal-title":"Haematologica"},{"key":"755_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0140-1","volume":"8","author":"P Ravi","year":"2018","unstructured":"Ravi P, Kumar SK, Roeker L, Gonsalves W, Buadi F, Lacy MQ, et al. Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. Blood cancer J. 2018;8:116.","journal-title":"Blood cancer J"},{"key":"755_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00587-0","volume":"11","author":"C Fern\u00e1ndez de Larrea","year":"2021","unstructured":"Fern\u00e1ndez de Larrea C, Kyle R, Rosi\u00f1ol L, Paiva B, Engelhardt M, Usmani S, et al. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood cancer J. 2021;11:192.","journal-title":"Blood cancer J"},{"key":"755_CR8","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015;33:2863\u20139.","journal-title":"J Clin Oncol"},{"key":"755_CR9","unstructured":"D\u2019Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. Journal of clinical oncology. 2022 May:JCO2102614."},{"key":"755_CR10","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. lancet Oncol. 2016;17:e328\u2013e46.","journal-title":"lancet Oncol"},{"key":"755_CR11","doi-asserted-by":"crossref","unstructured":"Yan W, Fan H, Xu J, Liu J, Li L, Du C, et al. The clinical characteristics and prognosis of patients with primary plasma cell leukemia (pPCL) according to the new IMWG definition criteria. Leukemia & lymphoma. 2022:1\u201310.","DOI":"10.1080\/10428194.2022.2098290"},{"key":"755_CR12","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1182\/blood-2012-05-408682","volume":"120","author":"NW van de Donk","year":"2012","unstructured":"van de Donk NW, Lokhorst HM, Anderson KC, Richardson PG. How I treat plasma cell leukemia. Blood 2012;120:2376\u201389.","journal-title":"Blood"},{"key":"755_CR13","doi-asserted-by":"publisher","first-page":"79517","DOI":"10.18632\/oncotarget.18535","volume":"8","author":"SH Jung","year":"2017","unstructured":"Jung SH, Lee JJ, Kim K, Suh C, Yoon DH, Min CK, et al. The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). Oncotarget 2017;8:79517\u201326.","journal-title":"Oncotarget"},{"key":"755_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0253-1","volume":"9","author":"EA Rojas","year":"2019","unstructured":"Rojas EA, Corchete LA, Mateos MV, Garc\u00eda-Sanz R, Misiewicz-Krzeminska I, Guti\u00e9rrez NC. Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background. Blood cancer J. 2019;9:90.","journal-title":"Blood cancer J"},{"key":"755_CR15","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1038\/leu.2012.107","volume":"26","author":"SZ Usmani","year":"2012","unstructured":"Usmani SZ, Nair B, Qu P, Hansen E, Zhang Q, Petty N, et al. Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols. Leukemia 2012;26:2398\u2013405.","journal-title":"Leukemia"},{"key":"755_CR16","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1158\/1078-0432.CCR-12-3461","volume":"19","author":"K Todoerti","year":"2013","unstructured":"Todoerti K, Agnelli L, Fabris S, Lionetti M, Tuana G, Mosca L, et al. Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome. Clin Cancer Res. 2013;19:3247\u201358.","journal-title":"Clin Cancer Res"},{"key":"755_CR17","doi-asserted-by":"publisher","first-page":"17543","DOI":"10.18632\/oncotarget.4028","volume":"6","author":"I Cifola","year":"2015","unstructured":"Cifola I, Lionetti M, Pinatel E, Todoerti K, Mangano E, Pietrelli A, et al. Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns. Oncotarget 2015;6:17543\u201358.","journal-title":"Oncotarget"},{"key":"755_CR18","doi-asserted-by":"crossref","unstructured":"Hofste Op Bruinink D, Kuiper R, van Duin M, Cupedo T, van der Velden VHJ, Hoogenboezem R, et al. Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile. Journal of clinical oncology. 2022:JCO2101217.","DOI":"10.1200\/JCO.21.01217"},{"key":"755_CR19","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2015.63.1929","volume":"34","author":"B Royer","year":"2016","unstructured":"Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, et al. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du My\u00e9lome. J Clin Oncol. 2016;34:2125\u201332.","journal-title":"J Clin Oncol"},{"key":"755_CR20","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/leu.2013.241","volume":"28","author":"P Musto","year":"2014","unstructured":"Musto P, Simeon V, Martorelli MC, Petrucci MT, Cascavilla N, Di Raimondo F, et al. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia 2014;28:222\u20135.","journal-title":"Leukemia"},{"key":"755_CR21","doi-asserted-by":"crossref","unstructured":"Niels WCJ, Van De Donk BDH, Schjesvold FH, Wu KL, Spada S, Broyl A, et al. Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12\/HOVON129 Study. Blood. 2019;134.","DOI":"10.1182\/blood-2019-125120"},{"key":"755_CR22","doi-asserted-by":"publisher","first-page":"804","DOI":"10.3324\/haematol.2009.013334","volume":"95","author":"MB Drake","year":"2010","unstructured":"Drake MB, Iacobelli S, van Biezen A, Morris C, Apperley JF, Niederwieser D, et al. Primary plasma cell leukemia and autologous stem cell transplantation. Haematologica 2010;95:804\u20139.","journal-title":"Haematologica"},{"key":"755_CR23","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.1038\/s41375-020-0830-0","volume":"34","author":"B Dhakal","year":"2020","unstructured":"Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, et al. Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia 2020;34:3338\u201347.","journal-title":"Leukemia"},{"key":"755_CR24","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/cncr.31718","volume":"125","author":"R Mina","year":"2019","unstructured":"Mina R, Joseph NS, Kaufman JL, Gupta VA, Heffner LT, Hofmeister CC, et al. Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. Cancer 2019;125:416\u201323.","journal-title":"Cancer"},{"key":"755_CR25","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41409-018-0392-1","volume":"54","author":"L Gowda","year":"2019","unstructured":"Gowda L, Shah M, Badar I, Bashir Q, Shah N, Patel K, et al. Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. Bone Marrow Transplant. 2019;54:1089\u201393.","journal-title":"Bone Marrow Transplant"},{"key":"755_CR26","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/leu.2011.312","volume":"26","author":"A Mahindra","year":"2012","unstructured":"Mahindra A, Kalaycio ME, Vela-Ojeda J, Vesole DH, Zhang MJ, Li P, et al. Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. Leukemia 2012;26:1091\u20137.","journal-title":"Leukemia"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00755-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00755-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00755-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T19:05:49Z","timestamp":1669057549000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00755-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,21]]},"references-count":26,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["755"],"URL":"https:\/\/doi.org\/10.1038\/s41408-022-00755-w","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,21]]},"assertion":[{"value":"18 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the institutional ethics committees of all participating institutions and was conducted in accordance with the Declaration of Helsinki. The committees waived the need for informed patient consent due to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"157"}}